SCHEMBL10072113

SCHEMBL10072113

CC(C)n1nc(Cl)ccc1=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMPR1B O00238 1/20 0.34
BMPR1A P36894 1/20 0.34
TGFBR1 P36897 1/20 0.34
ACVRL1 P37023 1/20 0.34
ACVR1 Q04771 1/20 0.34
ALDH1A1 P00352 3/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
HTT P42858 3/20 0.33
HRH3 Q9Y5N1 2/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
KDM4E B2RXH2 3/20 0.33
LMNA P02545 2/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
NFKB1 P19838 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10072451 0.81 L3MBTL1 (0.38) ALDH1A1SMN1; SMN2CYP1A2CYP2C19HTT
SCHEMBL5088809 0.79 KDM4E (0.31) ALDH1A1SMN1; SMN2KDM4EKMT2A
SCHEMBL1640803 0.78 HRH3 (0.49) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1
SCHEMBL8004896 0.77 EDNRB (0.37) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1
SCHEMBL8543642 0.75 POLB (0.35) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1
SCHEMBL22667221 0.75 BMPR1B (0.34) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1
SCHEMBL6134011 0.75 POLB (0.35) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1
Bicarbonate SCHEMBL23649996 0.73 L3MBTL1 (0.39) ALDH1A1SMN1; SMN2CYP1A2CYP2C19HTT
SCHEMBL25407851 0.73 POLB (0.36) ALDH1A1SMN1; SMN2CYP1A2CYP2C19POLB
SCHEMBL23370058 0.72 POLB (0.36) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612372-B2 Oxopyridazinyl-phenyl-carbonohydrazonoyl dicyanide compound and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2026-04-28 US disclosed
US-20240228469-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-07-11 US disclosed
US-20240217951-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-07-04 US disclosed
US-20230278963-A1 NOVEL OXOPYRIDAZINYL-PHENYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2023-09-07 US disclosed
EP-4169909-A1 NOVEL OXOPYRIDAZINYL-PHENYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF Korea Institute of Science and Technology (KR) 2023-04-26 EP disclosed
CN-115867279-A Novel oxopyridazinyl-phenyl-carbohydrazone acyldinitrile compounds and use thereof 韩国科学技术研究院 2023-03-28 CN disclosed
US-8318742-B2 Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives JANSSEN PHARMACEUTICA, N.V. (BE) 2012-11-27 US disclosed
US-20120028987-A1 Bicyclic Benzamides of 3-Or-4-Substituted 4-(Aminomethyl)-Piperidine Derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2012-02-02 US disclosed
US-8063070-B2 Bicyclic benzamides of 3-or 4-substituted 4-(aminomethyl)-piperidine derivatives JANSSEN PHARMACEUTICA, N.V. (BE) 2011-11-22 US disclosed
US-7790750-B2 Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
US-20100210657-A1 Bicyclic Benzamides of 3-or 4-Substituted 4-(Aminomethyl)-Piperidine Derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2010-08-19 US disclosed
US-RE40793-E1 Bicyclic benzamides of 3-or 4-substituted 4-(aminomethyl)-piperidine derivatives JANSSEN PHARMACEUTICA, N.V. (BE) 2009-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228469-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF PCSK9, PCSK7, PCSK6 BMPR1B 166/4885BMPR1A 309/4885TGFBR1 909/4885
US-20240217951-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF PCSK9, PCSK7, PCSK6 BMPR1B 165/4885BMPR1A 190/4885TGFBR1 668/4885
US-12612372-B2 Oxopyridazinyl-phenyl-carbonohydrazonoyl dicyanide compound and use thereof MAPT, MAP2, MAP1B BMPR1B 4284/4885BMPR1A 4380/4885TGFBR1 3440/4885
US-20230278963-A1 NOVEL OXOPYRIDAZINYL-PHENYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF DPP4, QDPR, DPYD BMPR1B 2343/4885BMPR1A 2958/4885TGFBR1 4763/4885
US-20120028987-A1 Bicyclic Benzamides of 3-Or-4-Substituted 4-(Aminomethyl)-Piperidine Derivatives HRH2, SLC10A2, HRH4 BMPR1B 3441/4885BMPR1A 3708/4885TGFBR1 3267/4885
US-20100210657-A1 Bicyclic Benzamides of 3-or 4-Substituted 4-(Aminomethyl)-Piperidine Derivatives HRH2, HRH4, PGC BMPR1B 3010/4885BMPR1A 3253/4885TGFBR1 3310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.